You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on HER2 biomarkers.
In the I-SPY 2 TRIAL, a subset of TNBC patients with elevated HER2 and EGFR phosphorylation responded to treatment with the HER2-inhibitor neratinib.
Strata will refer individuals with HER-2 mutations identified through its screening trial for consideration as subjects in Puma's SUMMIT trial.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.
At the AACR annual meeting, researchers presented results from the Phase II SUMMIT trial investigating the pan-HER-targeted therapy neratinib.
The new data supports the continued marketing of BioNTech's breast cancer subtyping assay as an alternative to IHC, and suggests added value for the test in assessing Ki-67 specifically.
Eleven new recommendations were issued to address appropriate HER2 testing and clinical guidance in individuals with advanced gastroesophageal adenocarcinoma.
The proteomic study, which built on past findings that HER2-negative tumors generate HER2-positive cells after treatment, suggests a role for combination therapy.
Members of the International Cancer Genome Consortium identified four main groups of HER2-positive breast tumors using genome sequencing and expression arrays.
The new system emphasizes the importance of tumor biology as an important prognostic indicator for women who undergo neoadjuvant therapy, the researchers said.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.